The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats

Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus

(2013) A. Kiyosue et al.   DIABETES OBESITY & METABOLISM

Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin

(2013) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes

(2013) Jeffrey A Pfefferkorn   Expert Opinion on Drug Discovery

Effects of a glucokinase activator on hepatic intermediary metabolism: study with13C-isotopomer-based metabolomics

(2012) Itzhak Nissim et al.   BIOCHEMICAL JOURNAL

Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans

(2012) Frédéric De Ceuninck et al.   BRITISH JOURNAL OF PHARMACOLOGY

Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat

(2012) M. Futamura et al.   DIABETOLOGIA

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

(2011) G. E. Meininger et al.   DIABETES CARE

Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice

(2011) Maria Sörhede Winzell et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Liver glucokinase: An overview on the regulatorymechanisms of its activity

(2011) María L. Massa et al.   IUBMB LIFE

Hepatic Glucokinase Expression Is Associated with Lipogenesis and Fatty Liver in Humans

(2011) Andreas Peter et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

(2011) Jeffrey A. Pfefferkorn et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs

(2011) J.-i. Eiki et al.   MOLECULAR PHARMACOLOGY

Overcoming retinoic acid receptor-α based testicular toxicity in the optimisation of glucokinase activators

(2011) Michael J. Waring et al.   MedChemComm

Glucokinase-activating GCKR Polymorphisms Increase Plasma Levels of Triglycerides and Free Fatty Acids, but do not Elevate Cardiovascular Risk in the Ludwigshafen Risk and Cardiovascular Health Study

(2010) D. H. Kozian et al.   HORMONE AND METABOLIC RESEARCH

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk

(2010) Josée Dupuis et al.   NATURE GENETICS

Diacylglycerol-mediated insulin resistance

(2010) Derek M Erion et al.   NATURE MEDICINE

The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver

(2009) Nicola L. Beer et al.   HUMAN MOLECULAR GENETICS

Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes

(2009) Gregory R. Bebernitz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Assessing the potential of glucokinase activators in diabetes therapy

(2009) Franz M. Matschinsky   NATURE REVIEWS DRUG DISCOVERY

Glucokinase and molecular aspects of liver glycogen metabolism

(2008) Loranne Agius   BIOCHEMICAL JOURNAL

Molecular Physiology of Mammalian Glucokinase

(2008) P. B. Iynedjian   CELLULAR AND MOLECULAR LIFE SCIENCES

Restoration of Hepatic Glucokinase Expression Corrects Hepatic Glucose Flux and Normalizes Plasma Glucose in Zucker Diabetic Fatty Rats

(2008) T. P. Torres et al.   DIABETES

Glucokinase activators in diabetes management

(2008) Matthew Coghlan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS